Vincent Ann
Vincent Ann has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Her-Shuyong Shia
Institute of Translational Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan
1 shared publication- Linling Chen
Translational Research laboratory, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
1 shared publication Nan Yong Hsu
Institute of Translational Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan
1 shared publication- Shikha Gaur
Department of Molecular Pharmacology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
1 shared publication - Vincent Hs Chang
The PhD Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
1 shared publication Wei-Chen Lin
Department of Molecular Pharmacology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
1 shared publication
Latest Publications
- Open Access
- 4 February 2014
- Published by Springer Nature in Molecular Cancer
- Vol. 13 (1) , 21
Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status
Cancer is the result of a multistep process of genomic alterations, including mutations in key regulatory proteins that result in loss of balanced gene expression and subsequent malignant transformation. Throughout the various stages of colorectal carcinoma (CRC), complex genetic alterations occur, of which over-expression of growth factors, such as vascular endothelial growth factor, fibroblast growth factor and platelet-derive growth factor and their corresponding receptor tyrosine kinases, have been shown to correlate with invasiveness, tumor angiogenesis, metastasis, recurrence, and poor prognosis of colorectal cancer. To evaluate the therapeutic effect, we combined Dovitinib, an orally bioavailable, potent inhibitor of class III-V receptor tyrosine kinases with chemotherapeutic drug, oxaliplatin in preclinical models of colon cancer.
- 4 February 2014
- Published by Springer Nature in Molecular Cancer
- Vol. 13 (1) , 21
Open AccessDovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status
Cancer is the result of a multistep process of genomic alterations, including mutations in key regulatory proteins that result in loss of balanced gene expression and subsequent malignant transformation. Throughout the various stages of colorectal carcinoma (CRC), complex genetic alterations occur, of which over-expression of growth factors, such as vascular endothelial growth factor, fibroblast growth factor and platelet-derive growth factor and their corresponding receptor tyrosine kinases, have been shown to correlate with invasiveness, tumor angiogenesis, metastasis, recurrence, and poor prognosis of colorectal cancer. To evaluate the therapeutic effect, we combined Dovitinib, an orally bioavailable, potent inhibitor of class III-V receptor tyrosine kinases with chemotherapeutic drug, oxaliplatin in preclinical models of colon cancer.